83 276

Cited 0 times in

Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study.

Authors
Lee, HS; Song, DH; Kim, JH; Lee, YM; Han, ES; Yoo, KJ
Citation
International clinical psychopharmacology, 10(2):67-72, 1995
Journal Title
International clinical psychopharmacology
ISSN
0268-13151473-5857
Abstract
A 6 week double-blind placebo-controlled trial of cyproheptadine augmentation of ongoing haloperidol treatment was conducted in 40 chronic schizophrenic in-patients. Cyproheptadine augmentation, compared to administration of haloperidol with placebo, did not produce a statistically significant improvement in psychotic symptoms. Cyproheptadine augmentation caused significant reduction in the extrapyramidal symptoms, which supports the atypical profile of antipsychotics. As to the neuroendocrinological effect, cyproheptadine augmentation did not reduce the plasma prolactin level but did induce a decrease in the plasma cortisol level. Although long-term follow-up studies are needed to confirm the results, this study suggests that cyproheptadine augmentation may be effective in treating chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics.
MeSH terms
AdultChronic DiseaseCyproheptadine/*therapeutic useDouble-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHaloperidol/*therapeutic useHumansHydrocortisone/bloodMalePlacebosProlactin/bloodSchizophrenia/blood/*drug therapyTime Factors
PMID
7673658
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Humanities & Social Medicine
AJOU Authors
이, 영문
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse